

## ANALYSIS

## Restoring invisible and abandoned trials: a call for people to publish the findings

 OPEN ACCESS

Unpublished and misreported studies make it difficult to determine the true value of a treatment. **Peter Doshi and colleagues** call for sponsors and investigators of abandoned studies to publish (or republish) and propose a system for independent publishing if sponsors fail to respond

Peter Doshi *postdoctoral fellow*<sup>1</sup>, Kay Dickersin *professor, director*<sup>2,3,4</sup>, David Healy *professor of psychiatry*<sup>5</sup>, S Swaroop Vedula *postdoctoral fellow*<sup>6</sup>, Tom Jefferson *researcher*<sup>7</sup>

<sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; <sup>2</sup>Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore; <sup>3</sup>Center for Clinical Trials, Johns Hopkins Bloomberg School of Public Health; <sup>4</sup>US Cochrane Center, Baltimore; <sup>5</sup>Bangor University, Bangor, UK; <sup>6</sup>Johns Hopkins University, Baltimore; <sup>7</sup>Cochrane Collaboration, Rome, Italy

Well designed and well performed randomised controlled trials are considered to provide the most reliable evidence on the effects of health related interventions. However, the credibility of findings from individual trials and from summaries of trials examining a similar research question (that is, systematic reviews and meta-analyses) has been undermined by numerous reporting biases in the published medical literature.<sup>1-14</sup> Reporting biases are often difficult to detect, but have the potential to discredit earnest efforts towards evidence based decision making.

Two basic problems of representation are driving growing concerns about relying on published research to reflect the truth.<sup>10-15</sup> The first is no representation (invisibility), which occurs when a trial remains unpublished years after completion. The second is distorted representation (distortion), which occurs when publications in medical journals present a biased or misleading description of the design, conduct, or results of a trial.<sup>1-6,10-14</sup> Both go against the fundamental scientific and ethical responsibility that all research on humans be used to advance knowledge and are symptomatic of a general culture of data secrecy. The end result is that the healthcare, biomedical research, and policy communities may, despite best intentions and best practices, end up drawing scientifically invalid conclusions based on only those parts of the evidence base they can see.

### A call to publish—or be published

Despite near universal agreement that reporting biases are harmful, efforts to correct the problem have largely focused on forward looking initiatives. Prospective registration of trials has

made major strides in ensuring that the biomedical community is aware of trials at their inception, but at best only around half of registered trials on ClinicalTrials.gov were registered before they began enrolling patients.<sup>16</sup> Recent studies have also shown that even when disclosure of study findings is mandated by law, results often remain invisible.<sup>17-19</sup> In addition, trial registration does not address the problems of invisibility and distortion for trials that took place before registers were widely used. Most importantly, those demanding correcting action lacked the data required to actually correct the scientific record. However, with increasing amounts of data entering the public domain, it is now becoming possible to move from words to action and publish (or republish) abandoned trials.

We have access to around 178 000 pages of previously confidential company research documents (table 1, box). For drugs such as paroxetine, quetiapine, and gabapentin, litigation over illegal off-label marketing put thousands of pages of trial reports in the public domain. Other trial reports, such as for oseltamivir and clopidogrel, were obtained through new freedom of information policies at the European Medicines Agency (EMA) that have revolutionised the public's ability to access trial data.<sup>20-23</sup> The documents are a substantial resource of information about trials. We expect that other independent groups will also have access to many additional trial reports.

The documents we have obtained include trial reports for studies that remain unpublished years after completion (such as Roche's study M76001, the largest treatment trial of oseltamivir, and Pfizer's study A945-1008, the largest trial of gabapentin for painful diabetic neuropathy). We also have thousands of pages of clinical study reports associated with trials that have been

Correspondence to: P Doshi, Reed Hall West, Room 201-C, 1620 McElderry Street, Baltimore, MD 21205, USA pdoshi@post.harvard.edu

RIATAR tool for documenting the RIAT process (as supplied by the author) (see <http://www.bmj.com/content/346/bmj.f2865?tab=related#webextra>)

published in scientific journals but shown to contain inaccuracies, such as Roche's oseltamivir study WV15671, GlaxoSmithKline's paroxetine study 329, and Pfizer's gabapentin study 945-291.<sup>3 12 24 25</sup> We consider these to be examples of abandoned trials: either unpublished trials for which sponsors are no longer actively working to publish or published trials that are documented as misrepresented but for which authors do not correct the record using established means such as a correction or retraction (which is an abandonment of responsibility) (box 1).<sup>25</sup> Because abandonment can lead to false conclusions about effectiveness and safety, we believe that it should be tackled through independent publication and republication of trials.

## A call to action

We call on institutions that funded and investigators who conducted abandoned trials to publish (in the case of unpublished trials) or formally correct or republish (in the case of misrepresented trials) their studies within the next year. This should allow sufficient time for manuscript preparation, peer review, and publication. We will email a copy of this article to manufacturers of trials listed in table 1, asking them to signal their intent to publish by sending an electronic response to the article within 30 days. We propose that if anyone who declares an intention to publish or correct does not do so within one year, all available data for such trials should be considered "public access data" that others are allowed to publish.

We are committed to seeing the findings from abandoned trials published and describe here a minimum set of criteria for responsible publication and republication of abandoned studies (box 2). We call this concept restoring invisible and abandoned trials (RIAT). As the concept develops, interested individuals and organisations will ideally work together to develop detailed policies aimed at improving trial publication practices. We see RIAT as a collaborative, global effort, and over the next year we hope to discuss and debate our proposal at appropriate venues.

The concept of publishing trials that we neither participated in, nor paid for, is an extension of what, in certain cases, we currently have in place: public use of epidemiological and clinical trial datasets from government sources<sup>30 31</sup> and public access to summary trial results on ClinicalTrials.gov.<sup>32</sup> Thus the scientific community has already accepted that investigators not associated with the original trial will produce and publish additional or confirmatory analyses. Furthermore, there are precedents for both publishing unpublished studies and republishing distorted studies. Examples include the description of design and findings from unpublished studies on the effects of nicotine on hypothalamic functions by using previously confidential (but now publicly available) company documents,<sup>33 34</sup> and reports of case studies derived from the clinical observations of neurosurgeon Harvey Cushing.<sup>35</sup> More recently, an investigator unconnected to Amgen's epoetin alfa study 930107 republished this trial, documenting serious distortions in the original publication.<sup>36 37</sup>

## Publishing trials, credibly

The major factor that makes publication of invisible and abandoned trials possible is the existence of clinical study reports (CSRs), documents produced by the pharmaceutical industry that include an unabridged and detailed summary of the planning, conduct, and results of a clinical trial.<sup>38</sup> The reports are rigidly structured according to guidelines that industry and regulators agreed to in 1995 (box 3) and are almost always

hundreds, if not thousands, of pages long. Manufacturers submit clinical study reports to the US Food and Drug Administration as part of applications for new drugs. In addition, the FDA typically also requires submission of the protocol and individual participant data. The European Medicines Agency does not routinely request individual participant data or clinical study reports.<sup>39</sup> Although clinical study reports may be unfamiliar to the academic world, and in our experience are typically not produced for trials sponsored by non-commercial funders, when those in industry or the FDA want to know what occurred in an industry sponsored trial, they may refer to a clinical study report. When industry statisticians wish to carry out further analyses of the data, they can turn to their database of individual participant data. The rest of us, however—doctors, medical and public health researchers, patients, and non-regulatory government agencies including many health technology assessment groups—are left with only what is in the public domain (usually at best, synopses of the trials in the form of journal articles) (figure 1).

Although by definition no journal publication exists for "unpublished trials," clinical study reports for industry funded trials often do exist for these unpublished trials, but they have been traditionally treated as secret.<sup>48 49</sup> However, litigation and new freedom of information rules in Europe have helped many clinical study reports to emerge in the public domain, thereby making the restorative authorship possible. In addition, some drug companies have recently pledged to release their reports.<sup>50 51</sup> Not all of the clinical study reports and other materials we have obtained are complete. However, many contain sufficient detail to form a comprehensive understanding of the trials and would enable someone to produce a journal length manuscript for publication.

We believe it is important to publish unpublished and other abandoned studies, even though they will at best represent a brief synopsis of all the publicly available data. This is because we live in a research and practice environment based on publications, and unpublished trials remain largely invisible. There is still no PubMed-like indexing system for unpublished clinical study reports. Moreover, most researchers will not have the time to sift through hundreds or thousands of pages to understand what occurred in a single clinical trial. We therefore need a shorthand representation, and the best we know of is journal publication.

To avoid a continuation of journal papers with selective reporting, we propose that trial publications adhere to reporting standards that ensure accountability. With a compression factor in some cases well above 1000:1 (table 2), summarising a clinical study report into a journal length manuscript inevitably requires value judgments about which information to include. These decisions should be transparent so that any bias can be identified and discussed. Responsible restorative authorship requires those publishing articles to also make the underlying trial data available simultaneously as an electronic appendix. In addition, there should be public access to an auditable record that documents which parts of the clinical study report (page numbers and paragraphs) were incorporated into the new publication, to help make restorative authors' value judgments about what to include in the summary explicit and transparent. We have designed the RIAT audit record (RIATAR), a tool to ensure this is done systematically, based on the CONSORT checklist for reporting randomised trials (see web appendix).<sup>52</sup>

Providing public access to both source documents and an audit record gives readers a quick way to find (and cross check) the relevant and more detailed information within the original clinical study report. We think that it should apply to all trials

**Box 1: Understanding the evidence iceberg***What's above the waterline*

**Published trial**—A trial for which there is a permanent public report that has the individual trial as the central focus and at a minimum presents a summary of the trial protocol and study results. Such reports usually appear in scientific journals. Reports of trials presented with other trials (such as in pooled analyses), do not by themselves confer “published” status

**Misreported trial**—A trial that the biomedical literature documents has been erroneously reported or reported in a biased manner, such as with outcome reporting biases. Journal editors will have to decide whether misreporting is serious enough to warrant republication

*What's partly above and partly below the waterline*

**Abandoned trial**—A trial can become abandoned in two ways. Firstly, a published trial can become abandoned when it is documented to be misreported and its authors do not correct their trial publication. Secondly, an unpublished trial can become abandoned when its sponsors are not working to ensure the trial is published. Detecting this form of abandonment is difficult. Comparing the amount of time that has elapsed since completion of follow-up to other published trials of the same drug and sponsor may help, but confirmation that an unpublished trial is abandoned may require contacting trial sponsors or clinical investigators

*What's (typically) below the waterline*

**Clinical study report**—A report using a highly structured format for integrated and complete reporting of the planning, execution, results, and analysis of a clinical trial (box 2)

**Individual participant data**—Data for each participant in a trial. This contrasts with aggregate or summary data, which is produced by combining data from multiple participants. Individual participant data allows for the replication of all analyses in study reports and exploration of further analyses

**Unpublished data**—Data of any type (measurements, analyses, narratives, or judgments) from a trial that have not been published, irrespective of whether the trial is published. Since trial reports in peer reviewed scientific journals typically provide only highly compressed summaries of trial data,<sup>26,27</sup> large amounts of unpublished data will remain for these trials

**Case report form**—The original paper or electronic forms on which individual participants' data (demographic, efficacy, safety, etc) are recorded during the clinical trial. The forms are typically the most “raw” form of detailed data available for understanding what happened in a clinical trial, and the data they contain are statistically analysed only after they have been entered into an electronic database of individual patient data. Forms can vary in length, from a few pages to hundreds of pages, and each trial can have multiple forms—for example, for different visits or for the different tests or procedures the participant undergoes.

**Trial protocol**—A document, written prospectively before recruiting participants into a trial, which records the general rules and intended methods of conducting, analysing, and reporting the trial. Many also include a statistical analysis plan. Trial protocols are tens to hundreds of pages in length. A protocol may be required by the research ethics board, a data and safety monitoring board, or a funding body. Any planned or actual changes from the original written protocol in the conduct should be documented with formal protocol amendments.<sup>28,29</sup>

**Investigators' brochure**—A document written by a sponsor and intended for clinical investigators interested in becoming involved in a study. It summarises the current body of evidence about an intervention under investigation, typically based on preclinical and human studies. The document is periodically updated in light of new information.

**Box 2: Proposal for restoring invisible and abandoned trials (RIAT)****1. Obtain clinical study reports and any other study data****2. Collect documentation of trial abandonment**

**For unpublished trials**—No primary publication detected by systematic search of the literature and/or confirmation from original trial sponsor or current responsible party that no publication exists

**For misreported trials**—Evidence of misreporting (ideally, published letters or other articles in the scientific literature or documentation of communication with the original trial publication author(s) detailing the misreporting) and a failure to correct the scientific record.

**3. Issue a “call to action” by publicly registering your possession of data sufficient for publication**

At least initially, this should be by an electronic response to this article and should include, as a minimum, trial identifiers, number of participants, date completed, publication status, pages in your holding, and level of access to trial data. This declaration offers original sponsors and trialists an opportunity to publish or formally correct their studies within the next 365 days. Send a copy of the rapid response by email to trial sponsors (and authors, for published trials), requesting confirmation of receipt.

**4. Collect documentation of the need for restoration**

Save time stamped copies of all rapid responses to this article (or other relevant websites) to document the time elapsed and consequent need for third party restoration.

**5. Presubmission inquiry to RIAT friendly journal**

Present editors with documentation from steps 1-4 and seek confirmation of editors' interest.

**6. Prepare and submit manuscript according to RIAT procedures**

- Include explanation (with references) in the Introduction of why this trial is being restored
- Provide auditable record of decisions (use RIATAR template), documenting which parts of the clinical study report (page number and paragraph) were used
- Report analyses specified in protocol
- Denote any analyses that were not prespecified
- Make all underlying data available electronically

published, irrespective of authorship, and follows on from previous calls by journal editors for improved research reporting standards.<sup>53-57</sup> It would enable independent verification of the accuracy of journal publications and permit better evidence synthesis and other forms of research.<sup>49, 58</sup>

RIAT reports should also provide the context for the study to help the readers understand why the trial is being restored. This

means including references to any previous publications of the trial and to details and evidence of the trial's abandonment. RIAT analyses should follow the analyses specified in the protocol (including any specified in amendments). Any other analyses are discouraged, but if done must be clearly noted as exploratory and not prespecified. At the same time, RIAT authors may wish to critically appraise the trials they report.

**Box 3: Clinical trials and clinical study reports**

Writing clinical study reports is now industry standard practice, but it was not always so. In the middle of the 20th century, the early years of randomised controlled trials, studies were small—initiated, carried out, and reported by a handful of investigators, often in an academic medical centre. Reporting was likewise more concise and simple—something that could be explained in a journal length article, with more detailed datasets available on request.

The 1980s, however, saw a dramatic rise in the complexity of clinical trials. Multisite, international trials funded by industry and use of contract research organisations, became common.<sup>40,41</sup> Whereas formerly those reporting trials had direct involvement in the conduct of the trial, the involvement of individual investigators in multicentre trials is often limited to a particular centre and a single “principal investigator” may see only the data they collected, not the complete dataset across all trial centres.<sup>42-45</sup>

In 1995, US, European, and Japanese regulators along with the respective industry trade organisations established a standardised way to organise a CSR to help simplify the new drug application process across global regulatory regimes.<sup>46</sup> The CSR’s length and complexity helped fuel the growing industry of paid medical writers, with people who had no involvement in the clinical trial authoring clinical study reports.<sup>47</sup>

The guideline defines a CSR as “an ‘integrated’ full report of an individual study of any therapeutic, prophylactic, or diagnostic agent . . . conducted in patients. The clinical and statistical description, presentations, and analyses are integrated into a single report, incorporating tables and figures into the main text of the report or at the end of the text, with appendices containing such information as the protocol, sample case report forms, investigator-related information, information related to the test drugs/investigational products including active control/comparators, technical statistical documentation, related publications, patient data listings, and technical statistical details such as derivations, computations, analyses, and computer output. The integrated full report of a study should not be derived by simply joining a separate clinical and statistical report.”<sup>46</sup>

This can be useful, but the critique should be clearly identifiable and placed in the discussion section.

Important details are still to be worked out (box 4 lists some of them), and we welcome discussion on how to get it right.

**Potentially controversial aspects of our proposal**

The idea of restorative writing may be seen as taking on responsibility and credit for other people’s actions, regardless of the trial’s sponsor, but it takes on a slightly different cast when trials are funded by commercial sponsors rather than public money. Some people may think that publications based on clinical study reports with which the authors have no connection is equivalent to intellectual property theft, but you cannot steal what is already in the public domain (and only in the public domain because a drug regulator or judge had the documents unconditionally released or the sponsor waived their confidentiality claims over the documents). The considerable discussion about the need for public access to trial data and data ownership has not yet resolved how to handle the thorny but important question of proper scientific credit.<sup>59-61</sup> RIAT authorship will not usurp proper credit for a trial. Rather, it will show how problematic the concepts of authorship and results reporting are in the modern clinical trial. RIAT authors would be able to claim credit for bringing to light what was previously invisible or distorted but not for carrying out the trial.

In the case of the Roche sponsored oseltamivir trials, we have so far identified eight different layers of responsibility, perhaps partially overlapping: those who designed the trial, those who sponsored it, those who conducted it, those who analysed the data, those who wrote or assembled the clinical study report, those who decided the publication policy, those who decided which parts to publish (and in some cases not to publish), those who presented results at meetings or conferences, and, lastly, those who put their names to the published manuscript. None of these roles has a clear thread of accountability and authors of the published trials have confirmed that they did not have access to the underlying study data.<sup>45, 62</sup> In sum, in the context of the modern clinical trial research enterprise, the traditional journal article publication model obscures responsibility more than it illuminates.

Is restorative writing fundamentally different from professional medical writing and “ghost writing”? One important difference is that hired medical writers are paid for their services by those who stand to gain from the publication and restorative authors are not. Restorative authors are also likely to have access to

more detailed trial records than medical writers. Another difference is that medical writers are often instructed to insert “key messages” in publication ready manuscripts.<sup>11, 63</sup> Finally, medical writers are often unacknowledged in the publication and so are not accorded any responsibility for the work they produce. By contrast, RIAT authors will take full responsibility for publishing abandoned studies, although we will refer to RIAT to make it clear that the article is a work of restoration, not primary authorship. We are also contemplating how best to document RIAT authorship in our CVs: at a minimum, such publications need to be listed under a separate heading, identifying them as such.

Recently, a group of drug manufacturers and medical journal editors published “ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research,” aimed at eliminating reporting biases.<sup>64</sup> Their recommendations do not go far enough to address the problems. They do not mention publishing abandoned trials and ignore responsibility for correcting reporting biases persisting in existing trial publications. Furthermore, their recommendation to “make public all data” refers to publication of journal article length manuscripts rather than the full clinical study reports, individual participant data, investigators’ brochures, case report forms, and many other of the semi-secret documents that would help people to understand a trial and its place in the research or regulatory approval programme—meaning the published results would have to be taken on trust without the possibility of verification.

Will the publication of detailed clinical study reports enable subsequent ill intentioned or otherwise misleading analyses by others (such as spurious findings from data dredging)? We challenge readers to provide an example of open clinical trial data sharing that has led to major public health harm. If RIAT evokes the spectre of data mining, it is important to remember that we currently have no way to judge the fidelity of the process of synthesising thousands of pages of a clinical study report into a journal publication. RIAT publication is important even for poorly conducted or unethical studies that many editors may not feel merit publication. Without public documentation that a trial was poorly done, researchers will be left guessing about the value of the study. A very brief trial report (without results if they would be misleading) may suffice.

Finally, some people may argue that RIAT republication of a misreported study is muddying the published record for dubious gain, especially with older trials. We believe that correcting the scientific record is preferable to ignoring inaccuracies. If the accompanying data support what is reported in the RIAT



**Box 4: Issues for further discussion and development**

- Should the original trial investigators have the right to join a group of RIAT authors?
- Should RIAT authors contact original investigators for help in interpreting trial documents?
- Should old trials that are going to be subject to RIAT publication be registered in trial registries such as ClinicalTrials.gov (assuming this becomes possible)? Should registration preclude other restorative author teams from using the same data?
- Should RIAT publication related clinical study reports and audit records be stored on the publishing journal's server or is a publicly available database required?
- Where should the declaration of intent to publish a RIAT trial be published?
- How should RIAT publications be cited? Should restoration be clearly identified in the publication title or the authorship byline? If yes, how?
- What (if any) additional rules or safeguards should RIAT authors apply to ensure patient confidentiality of individual patient data and clinical report forms that are already in the public domain?
- For misreported articles, what level of narrative detail regarding the misreporting should the RIAT publication contain?
- Should RIAT authors seek approval from an appropriate research ethics committee before publishing a trial with unclear prior ethical basis?

republication, doubts about which publication is correct should not be a problem.

## Call for restorative authors and participating journals

The data we have obtained (table 1<sup>1</sup>) relate to only a small fraction of the masses of abandoned clinical trials. We call on others to join us, to contribute trial documents they have obtained from public sources that need publishing or republishing, and to help us with the writing. We need volunteers to act in place of those who should have but did not make trial reports visible and accessible.

Litigation and freedom of information promise to usher increasing amounts of clinical trial documents into the public domain. This reality necessitates an urgent discussion about what constitutes this new public commons and how it should function. Should there be a central repository for once secret trial documents and, if so, who should or can responsibly house, index, and maintain a public database of documents that span regulatory and legal boundaries? The tens of millions of pages of internal tobacco industry documents released in 1998 illustrate the enormity and importance of rising to the challenge.<sup>65</sup>

Endorsement of the concept of restorative authorship by medical journal editors will help the effort to complete and correct the scientific record. Journals can signal their willingness to accept RIAT publications by including details in their “instructions for authors.” We suggest that journals ask restorative authors to provide documentation of a trial's status as abandoned, the provenance of data on which the RIAT publication is written (to ensure it is in the public domain), and to agree to submit the clinical study report and all other data used to write the manuscript as well as an audit record documenting what data were used. We suggest that to reduce wasted time on behalf of both authors and editors, authors submit a presubmission inquiry to discuss their case.

Our declaration to publish will be the first step towards public and open debate on an issue that affects everyone and has for too long been the preserve of people acting behind closed doors.

We thank Yuko Hara, Iain Chalmers, and Betsy Humphries for many helpful conversations and comments on the idea and draft manuscript. We also wish to thank the many others who made important contributions during the peer review process: external peer reviewers James Miller, Douglas McCrory, Margaret Winker, Emma Veitch, Andrew Vickers, Deborah Zarin, and Tony Tse and the BMJ editors, particularly Elizabeth Loder.

Contributors and sources: PD conceived of RIAT and wrote the first draft of the manuscript with TJ. Numerous oral and written discussions among all authors shaped the RIAT concept. All authors contributed to the many rounds of editing. PD is guarantor.

Competing interests: We have read and understood the BMJ Group policy on declaration of interests and declare the following: PD and TJ have published on influenza antivirals and received a UK National Institute of Health research grant for the update and amalgamation of two Cochrane reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. PD received support from the European Respiratory Society for travel to the society's September 2012 annual congress where he gave an invited talk. He is funded by an institutional training grant from the US Agency for Healthcare Research and Quality. AHRQ had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. KD served as an expert witness in 2008 litigation against Pfizer relating to gabapentin. Funds from this effort were donated by the plaintiff's lawyers to Johns Hopkins to support academic scholarship in the area of reporting biases. DH has been an expert witness in legal cases that have brought to light issues surrounding non-publication of trials and ghostwriting and an action by New York State that led some of the documents this article references to come to light. SSV was paid by the plaintiffs' lawyers for assisting KD with preparing her expert witness report in 2008 litigation against Pfizer. SSV's research related to reporting of trials in off-label uses of gabapentin was supported by an academic scholarship established at Johns Hopkins using funds from KD's effort as an expert witness in the 2008 litigation against Pfizer. TJ receives royalties from his books published by Blackwell and Il Pensiero Scientifico Editore. He is occasionally interviewed by market research companies for anonymous interviews about Phase 1 or 2 products. He was a consultant in a legal case regarding oseltamivir. Provenance and peer review: Not commissioned; externally peer reviewed.

- 1 Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess* 2010;14(8):1-193.
- 2 Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the food and drug administration: review of publication and presentation. *PLoS Med* 2008;5:e217.
- 3 Doshi P, Jones M, Jefferson T. Rethinking credible evidence synthesis. *BMJ* 2012;344:d7898.
- 4 Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004;291:2457-65.
- 5 Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. *Trials* 2011;12:249.
- 6 Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med* 2008;358:252-60.
- 7 Dickersin K, Min YI. Publication bias: the problem that won't go away. *Ann N Y Acad Sci* 1993;703:135-46; discussion 146-8.
- 8 Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database Syst Rev* 2009;1:MR000006.
- 9 Melander H. Evidence based medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. *BMJ* 2003;326:1171-3.

- 10 McGauran N, Wieseler B, Kreis J, Schuler Y-B, Kolsch H, Kaiser T. Reporting bias in medical research - a narrative review. *Trials* 2010;11:37.
- 11 Sisondo S, Doucet M. Publication ethics and the ghost management of medical publication. *Bioethics* 2009;24:273-83.
- 12 Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. *N Engl J Med* 2009;361:1963-71.
- 13 Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev* 2012;1:CD008965.
- 14 Vedula SS, Li T, Dickersin K. Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. *PLoS Med* 2013;10:e1001378.
- 15 Chan A-W. Bias, spin, and misreporting: time for full access to trial protocols and results. *Plos Med* 2008;5:e230.
- 16 Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. *JAMA* 2012;307:1838-47.
- 17 Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. *BMJ* 2012;344:d7373.
- 18 Law MR, Kawasumi Y, Morgan SG. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. *Health Affairs* 2011;30:2338-45.
- 19 Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database — update and key issues. *N Engl J Med* 2011;364:852-60.
- 20 European Medicines Agency. European Medicines Agency policy on access to documents related to medicinal products for human and veterinary use. 2010. [www.ema.europa.eu/docs/en\\_GB/document\\_library/Other/2010/11/WC500099473.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/11/WC500099473.pdf).
- 21 European Medicines Agency. Output of the European Medicines Agency policy on access to documents related to medicinal products for human and veterinary use. 2010 [www.ema.europa.eu/docs/en\\_GB/document\\_library/Regulatory\\_and\\_procedural\\_guideline/2010/11/WC500099472.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/11/WC500099472.pdf).
- 22 HMA/EMA Working Group on Transparency. HMA/EMA guidance document on the identification of commercially confidential information and personal data within the structure of the marketing authorisation (MA) application - release of information after the granting of a marketing authorisation. 2012 [www.ema.europa.eu/docs/en\\_GB/document\\_library/Other/2012/03/WC500124536.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/03/WC500124536.pdf).
- 23 Doshi P, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. *JAMA Intern Med* 2013;173:380-2.
- 24 Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: Selective reporting of study 329. *Int J Risk Safety Med* 2008;20:73-81.
- 25 Newman M. The rules of retraction. *BMJ* 2010;341:c6985.
- 26 Boulton G, Rawlins M, Vallance P, Walport M. Science as a public enterprise: the case for open data. *Lancet* 2011;377:1633-5.
- 27 Fromer M. Public access to research data: a right to know or off limits? *Oncology Times* 2001;23:52-4.
- 28 Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200-7.
- 29 Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.
- 30 Department of Energy. Comprehensive epidemiologic data resource. 2012 [www.orau.gov/cedr/](http://www.orau.gov/cedr/).
- 31 National Heart Lung and Blood Institute. Women's Health Initiative. 2011. [www.nhlbi.nih.gov/whi/references.htm](http://www.nhlbi.nih.gov/whi/references.htm).
- 32 Food and Drug Administration. Food and Drug Administration Amendments Act of 2007.
- 33 Slade J, Bero LA, Hanauer P, Barnes DE, Glantz SA. Nicotine and Addiction. The Brown and Williamson documents. *JAMA* 1995;274:225-33.
- 34 Hersch J, Libert O, Rogg-Effron C. Final report on project hippo I. 1962. <http://legacy.library.ucsf.edu/tid/buc72d00/pdf>.
- 35 Pendleton C, Olivi A, Brem H, Quiñones-Hinojosa A. Harvey Cushing's early treatment of meningiomas: the untold story. *World Neurosurgery* 2011 Nov <http://linkinghub.elsevier.com/retrieve/pii/S1878875011010011>.
- 36 Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. *Kidney Int* 2012;82:235-41.
- 37 Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med* 1998;339:584-90.
- 38 Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. *BMJ Open* 2013;3:e002496.
- 39 European Medicines Agency. Note for guidance on the inclusion of appendices to clinical study reports in marketing authorisation applications. 2004. [www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2009/09/WC500003638.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003638.pdf).
- 40 Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. *N Engl J Med* 2009;360:816-23.
- 41 Mirowski P, Van Horn R. The contract research organization and the commercialization of scientific research. *Soc Stud Sci* 2005;35:503-48.
- 42 Mello MM, Claridge BR, Studdert DM. Academic medical centers' standards for clinical-trial agreements with industry. *N Engl J Med* 2005;352:2202-10.
- 43 Healy D. *Pharmageddon*. 1st ed. University of California Press, 2012.
- 44 Blumsohn A. Authorship, ghost-science, access to data and control of the pharmaceutical scientific literature: who stands behind the word? *AAAS Professional Ethics Report* 2006;19:1-4.
- 45 Korn D, Ehringhaus S. Principles for strengthening the integrity of clinical research. *PLoS Clin Trials* 2006. [www.ncbi.nlm.nih.gov/pmc/articles/PMC1488888/](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1488888/).
- 46 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Structure and content of clinical study reports: E3. 1995 [www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Efficacy/E3/E3\\_Guideline.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf).
- 47 Hendrick R. Ghosts in the machine. *BMJ* 2011;343:d7860.
- 48 Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. *PLoS Med* 2012;9:e1001201.
- 49 Unlu M. It is time: why the FDA should start disclosing drug trial data. *Mich Telecomm Tech L Rev* 2010;16:511-45.
- 50 Hoffmann-La Roche. Roche launches new process for accessing clinical trial data Press release, 26 Feb 2013. [www.roche.com/media/media\\_releases/med-cor-2013-02-26.htm](http://www.roche.com/media/media_releases/med-cor-2013-02-26.htm).
- 51 GlaxoSmithKline. GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges. Press release, 11 Oct 2012. [www.gsk.com/media/press-releases/2012/GSK-announces-further-initiatives-to-tackle-global-health-challenges.html](http://www.gsk.com/media/press-releases/2012/GSK-announces-further-initiatives-to-tackle-global-health-challenges.html).
- 52 Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c332.
- 53 Hrynaszkiwicz I, Norton ML, Vickers AJ, Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. *BMJ* 2010;340:c181.
- 54 Laine C, Goodman SN, Griswold ME, Sox HC. Reproducible research: moving toward research the public can really trust. *Ann Intern Med* 2007;146:450-3.
- 55 Groves T. BMJ policy on data sharing. *BMJ* 2010 Jan 28;340:c564.
- 56 Hanson B, Sugden A, Alberts B. Making data maximally available. *Science* 2011;331:649.
- 57 Bauchner H, Fontanarosa PB. Restoring confidence in the pharmaceutical industry. *JAMA* 2013;309:607-9.
- 58 Eichler H-G, Abadie E, Breckenridge A, Leufkens H, Rasi G. Open clinical trial data for all? a view from regulators. *PLoS Med* 2012;9:e1001202.
- 59 Rennie D, Yank V, Emanuel L. When authorship fails. A proposal to make contributors accountable. *JAMA* 1997;278:579-85.
- 60 Smith R. Authorship is dying: long live contributorship. *BMJ* 1997;315:696.
- 61 Horton R. The signature of responsibility. *Lancet* 1997;350:5-6.
- 62 Cohen D. Complications: tracking down the data on oseltamivir. *BMJ* 2009;339:b5387.
- 63 Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold "HRT". *PLoS Med* 2010;7:e1000335.
- 64 Mansi BA, Clark J, David FS, Gesell TM, Glasser S, Gonzalez J, et al. Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective. *Mayo Clin Proc* 2012;87:424-9.
- 65 University of California. Legacy tobacco documents library. 2007. <http://legacy.library.ucsf.edu/>.
- 66 Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. *Am J Psychiatry* 2005;162:1351-60.
- 67 Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. *J Clin Psychiatry* 2009;70:487-99.
- 68 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996;348:1329-39.
- 69 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494-502.
- 70 Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of clopidogrel as adjunctive reperfusion therapy-thrombolysis in myocardial infarction (CLARITY-TIMI) 28 trial. *Am Heart J* 2005;149:227-33.
- 71 Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med* 2005;352:1179-89.
- 72 Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet* 2005;366:1607-21.
- 73 Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP Jr, et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. *Circulation* 2008;117:553-9.
- 74 Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. *J Affect Disord* 2009;112:36-49.
- 75 Rümke HC, Bayas J-M, De Juanes J-R, Caso C, Richardus JH, Campins M, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. *Vaccine* 2008;26:2378-88.
- 76 Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry* 2001;40:762-72.
- 77 Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. *J Child Adolesc Psychopharmacol* 2006;16:59-75.
- 78 Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD, et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? *J Child Adolesc Psychopharmacol* 2003;13(suppl 1):S19-29.
- 79 Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. *J Am Acad Child Adolesc Psychiatry* 2003;42:22-9.
- 80 Emslie GJ, Wagner KD, Kutcher S, Krulwicz S, Fong R, Carpenter DJ, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2006;45:709-19.
- 81 Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2004;43:1387-96.
- 82 Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. *Neuropsychopharmacol* 2006;31:1274-85.
- 83 Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. *Arch Gen Psychiatry* 2004;61:1153-62.
- 84 Fong R, Carpenter D, Lipschitz A, Krulwicz S, Machin A, Wilkinson C. Long-term safety and tolerability of paroxetine. *J Child Adolesc Psychopharmacol* 2005;15:856.
- 85 Matsumoto K, Ogawa N, Nerome K, Numazaki Y, Kawakami Y, Shirato K, et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. *Antivir Ther* 1999;4:61-8.
- 86 Murphy KR, Eivindson A, Pauksens K, Stein WJ, Teller G, Watts R, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. *Clin Drug Investig* 2000;20:337-49.

- 87 Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. *Pediatr Infect Dis J* 2000;19:410-7.
- 88 Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. *N Engl J Med* 2000;343:1282-9.
- 89 Puhakka T, Lehti H, Vainionpää R, Jormanainen V, Pulkkinen M, Sharp S, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. *Scand J Infect Dis* 2003;35:52-8.
- 90 Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. *J Infect Dis* 2002;186:1582-8.
- 91 LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, Bettis R, et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. *Clin Ther* 2007;29:1579-90; discussion 1577-8.
- 92 Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. *N Engl J Med* 1997;337:874-80.
- 93 Peng AW, Hussey EK, Moore KH. A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. *J Clin Pharmacol* 2000;40:242-9.
- 94 Schilling M, Povinelli L, Krause P, Gravenstein M, Ambrozaitis A, Jones HH, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. *Vaccine* 1998;16:1771-4.
- 95 Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. *J Antimicrob Chemother* 1999;44(suppl 2):23-9.
- 96 Gravenstein S, Drinka P, Osterweil D, Schilling M, Krause P, Elliott M, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. *J Am Med Dir Assoc* 2005;6:359-66.
- 97 Ambrozaitis A, Gravenstein S, van Essen GA, Rubinstein E, Balciuniene L, Stikleryte A, et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. *J Am Med Dir Assoc* 2005;6:367-74.
- 98 Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. *JAMA* 1999;282:31-5.
- 99 Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. *J Infect Dis* 1999;180:254-61.
- 100 Kaiser L, Henry D, Flack NP, Keene O, Hayden FG. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. *Clin Infect Dis* 2000;30:587-9.
- 101 Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. *Lancet* 1998;352:1877-81.
- 102 Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. *J Infect* 2000;40:42-8.
- 103 Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. *PLoS One* 2009;4:e4384.
- 104 Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. *Pediatrics* 2010;126:e762-70.
- 105 Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. *JAMA* 1998;280:1831-6.
- 106 Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. *Bipolar Disord* 2000;2:249-55.
- 107 Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. *Headache* 2001;41:119-28.
- 108 Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. *Pain* 2002;99:557-66.
- 109 Gordh TE, Stubhaug A, Jensen TS, Arnér S, Biber B, Boivie J, et al. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. *Pain* 2008;138:255-66.
- 110 Gómez-Pérez FJ, Perez-Monteverde A, Nascimento O, Aschner P, Tagle M, Fichtner K, et al. Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. *Br J Diabetes Vasc Dis* 2004;4:173-8.
- 111 Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. *J Clin Oncol* 2004;22:2909-17.
- 112 Vieta E, Manuel Goikolea J, Martínez-Arán A, Comes M, Verger K, Masramon X, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. *J Clin Psychiatry* 2006;67:473-7.
- 113 Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. *J Clin Psychopharmacol* 2000;20:28-34.
- 114 Massana J, Möller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. *Int Clin Psychopharmacol* 1999;14:73-80.
- 115 Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. *Int Clin Psychopharmacol* 2003;18:9-14.
- 116 Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. *J Psychopharmacol* 2006;20:91-6.
- 117 Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. *J Clin Psychopharmacol* 2006;26:121-7.
- 118 Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. *N Engl J Med* 1999;341:1336-43.
- 119 Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. *Lancet* 2000;355:1845-50.
- 120 Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. *JAMA* 2000;283:1016-24.
- 121 Hayden FG, Jennings L, Robson R, Schiff G, Jackson H, Rana B, et al. Oral oseltamivir in human experimental influenza B infection. *Antivir Ther (Lond)* 2000;5:205-13.
- 122 Welliver R, Monto AS, Carewicz O, Schattman E, Hassman M, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. *JAMA* 2001;285:748-54.
- 123 Peters PH Jr, Gravenstein S, Norwood P, De Bock V, Van Couter A, Gibbens M, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. *J Am Geriatr Soc* 2001;49:1025-31.
- 124 Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. *Pediatr Infect Dis J* 2001;20:127-33.
- 125 Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. *Pediatr Infect Dis J* 2005;24:225-32.
- 126 Dutkowski R, Smith JR, Davies BE. Safety and pharmacokinetics of oseltamivir at standard and high dosages. *Int J Antimicrob Agents* 2010;35:461-7.
- 127 Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. *J Infect Dis* 2004;189:440-9.
- 128 Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. *Diabetes Care* 2000;23:1605-11.

Accepted: 5 April 2013

Cite this as: *BMJ* 2013;346:f2865

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>.

## Tables

Table 1 | Clinical study reports in our possession

Trial identifiers	No of participants	Year completed*	Published	No of pages†	Level of access to trial data		
					Trial protocol	IPD	CRFs
Amgen epoetin alfa study 930107	1265	1997§	Yes <sup>36,37</sup>	289	No	No	No
AstraZeneca quetiapine study 015	331	1995		3459	Yes	No	No
AstraZeneca quetiapine study 041	532	2002		185	No	No	No
AstraZeneca quetiapine study 049	542	2003	Yes <sup>66</sup>	8027	Yes	Yes	No
AstraZeneca quetiapine study 135	509	2005		1507	No	No	No
AstraZeneca quetiapine study 125	574	2005	Yes <sup>67</sup>	4582	Yes	Yes	No
AstraZeneca quetiapine study 127	1953	2006		6434	Yes	No	No
AstraZeneca quetiapine study 126	1461	2006		6135	Yes	No	No
Bristol-Myers Squibb clopidogrel study CAPRIE	19185	1996	Yes <sup>68</sup>	211	Yes	No	No
Bristol-Myers Squibb clopidogrel study CURE	12562	2000	Yes <sup>69</sup>	110	No	No	No
Bristol-Myers Squibb clopidogrel study CLARITY	3491	2005	Yes <sup>70,71</sup>	114	No	No	No
Bristol-Myers Squibb clopidogrel study COMMIT	45852	2005	Yes <sup>72</sup>	56	No	No	No
Bristol-Myers Squibb clopidogrel study PICOLO	92	2006	Yes <sup>73</sup>	101	No	No	No
Bristol-Myers Squibb aripiprazole study CN138135	480	2006	Yes <sup>74</sup>	9406	Yes	Yes	No
GSK H5N1 pandemic influenza vaccine studies H5N1-008, H5N1-011 EXT 008	5075	2006	Yes <sup>75</sup>	208	No	No	No
GSK paroxetine study 329	275	1998	Yes <sup>76</sup>	6022	Yes	Yes	No
GSK paroxetine study 377	286	1998	Yes <sup>77</sup>	4659	Yes	Yes	No
GSK paroxetine study 453	339	1998	Yes <sup>78</sup>	15440	Yes	Yes	No
GSK paroxetine study 511	125	1999	Yes <sup>79</sup>	400	Yes	Yes	No
GSK paroxetine study 701	206	2001	Yes <sup>80</sup>	4016	Yes	Yes	No
GSK paroxetine study 704	207	2001	Yes <sup>81</sup>	3896	Yes	Yes	No
GSK paroxetine study 715	62	2001	Yes <sup>82</sup>	1260	Yes	Yes	No
GSK paroxetine study 676	322	2001	Yes <sup>83</sup>	5855	Yes	Yes	No
GSK paroxetine study 716	265	2002	Yes <sup>84</sup>	5473	Yes	Yes	No
GSK zanamivir study 167-101	319	2000		708	No	No	No
GSK zanamivir study 167T3-11	145	2001		789	No	No	No
GSK zanamivir study JNAI-01	116	1995	Yes <sup>85</sup>	410	No	No	No
GSK zanamivir study JNAI-04	50	1996		589	No	No	No
GSK zanamivir study JNAI-07	333	1999		1737	No	No	No
GSK zanamivir study NAI30008	525	2000	Yes <sup>86</sup>	779	No	No	No
GSK zanamivir study NAI30009	471	1999	Yes <sup>87</sup>	469	No	No	No
GSK zanamivir study NAI30010	1158	1999	Yes <sup>88</sup>	633	No	No	No
GSK zanamivir study NAI30011	466	2000		358	No	No	No
GSK zanamivir study NAI30012	358	2001		709	No	No	No
GSK zanamivir study NAI30015	588	2001	Yes <sup>89</sup>	480	No	No	No
GSK zanamivir study NAI30020	334	2001		205	No	No	No
GSK zanamivir study NAI30028	266	2001		207	No	No	No
GSK zanamivir study NAI30031	1291	2001	Yes <sup>90</sup>	1122	No	No	No
GSK zanamivir study NAI30034	3363	2001	Yes <sup>91</sup>	467	No	No	No
GSK zanamivir study NAI30035	220	1995	Yes <sup>92</sup>	427	No	No	No
GSK zanamivir study NAI30036	64	1995	Yes <sup>93</sup>	253	No	No	No
GSK zanamivir study NAI30037	257	1997	Yes <sup>94</sup>	200	No	No	No
GSK zanamivir study NAI30038	777	1998	Yes <sup>95</sup>	537	No	No	No
GSK zanamivir study NAI30039	1116	2000	Yes <sup>96</sup>	376	No	No	No



Table 1 (continued)

Trial identifiers	No of participants	Year completed*	Published	No of pages†	Level of access to trial data		
					Trial protocol	IPD	CRFs
GSK zanamivir study NAIA3004	489	2000	Yes <sup>97</sup>	391	No	No	No
GSK zanamivir study NAIA3005	1107	1998	Yes <sup>98</sup>	355	No	No	No
GSK zanamivir study NAIB2008	1256	1996	Yes <sup>99</sup>	527	No	No	No
GSK zanamivir study NAIB2009	577	1996	Yes <sup>100</sup>	364	No	No	No
GSK zanamivir study NAIB2005	198	1995	Yes <sup>92</sup>	372	No	No	No
GSK zanamivir study NAIB2006	115	1995		240	No	No	No
GSK zanamivir study NAIB2007	554	1996		461	No	No	No
GSK zanamivir study NAIB3001	455	1997	Yes <sup>101</sup>	465	No	No	No
GSK zanamivir study NAIB3002	356	1998	Yes <sup>102</sup>	454	No	No	No
GSK zanamivir study PE-01	44	1996		392	No	No	No
Merck rofecoxib study 078	1457	2003		392	Yes	No	No
Novartis Fluad study V87P1	486	2007	Yes <sup>103</sup>	3670	Yes	Yes	No
Novartis Fluad study V87P6	471	2009	Yes <sup>104</sup>	5483	Yes	Yes	No
Pfizer atorvastatin study 981080	335	1998		518	Yes	Part	No
Pfizer gabapentin study 879-201	87	1988		925	Yes	No	No
Pfizer gabapentin study 945-210**	165	1997	Yes <sup>105</sup>	1188	Yes	Yes	No
Pfizer gabapentin study 945-209	117	1997	Yes <sup>106</sup>	231	Yes	Yes	No
Pfizer gabapentin study 945-220	145	1998	Yes <sup>107</sup>	4166	Yes	Yes	No
Pfizer gabapentin study 945-217	157	1999		4336	Yes	Yes	No
Pfizer gabapentin study 1032-001	483	1999		437	Yes	Yes	No
Pfizer gabapentin study 945-224**	325	1999		3214	Yes	Yes	No
Pfizer gabapentin study 945-306**	307	2000	Yes <sup>108</sup>	1358	Yes	Yes	No
Pfizer gabapentin study 1035-001	325¶	2000		371	Yes	Yes	No
Pfizer gabapentin study 1032-004	206	2000		463	Yes	Yes	No
Pfizer gabapentin study 1032-002	262	2000		580	Yes	Yes	No
Pfizer gabapentin study 1035-002	200	2000		380	Yes	Yes	No
Pfizer gabapentin study 1032-003	212	2000		228	Yes	Yes	No
Pfizer gabapentin study 945-271**	120	2001	Yes <sup>109</sup>	111	Yes	No	No
Pfizer gabapentin study 945-411**	339	2001	Yes <sup>110</sup>	492	Yes	Yes	No
Pfizer gabapentin study 945-276**	121	2002	Yes <sup>111</sup>	41	No	No	No
Pfizer gabapentin study A945-1008**	389	2003		63	Yes	Yes	No
Pfizer gabapentin study 945-291	42	2004	Yes <sup>112</sup>	23	No	No	No
Pfizer reboxetine study 9	50	1989		327	Yes	Yes	No
Pfizer reboxetine study 91	56	1990	Yes <sup>113</sup>	1715	Yes	Part	No
Pfizer reboxetine study 8	258	1991‡		711	Yes	Part	No
Pfizer reboxetine study 32a	50	1991		307	Yes	Yes	No
Pfizer reboxetine study 17	256	1992		1466	Yes	Yes	No
Pfizer reboxetine study 15	339	1992		2096	Yes	Yes	No
Pfizer reboxetine study 13	358	1993		2599	Yes	Yes	No
Pfizer reboxetine study 16	168	1993	Yes <sup>114</sup>	1186	Yes	Yes	No
Pfizer reboxetine study 35	347	1994		2537	Yes	Yes	No
Pfizer reboxetine study 49	212	1998		65	No	No	No
Pfizer reboxetine study 50	450	1999		148	No	No	No
Pfizer reboxetine study 45	350	1999		89	No	No	No
Pfizer reboxetine study 34	128	2000		2079	Yes	Part	No
Pfizer reboxetine study 47	774	2000	Yes <sup>115</sup>	133	No	No	No
Pfizer reboxetine study 46	787	2000		112	No	No	No

Table 1 (continued)

Trial identifiers	No of participants	Year completed*	Published	No of pages†	Level of access to trial data		
					Trial protocol	IPD	CRFs
Pfizer reboxetine study 52	325	2000	Yes <sup>116</sup>	92	No	No	No
Pfizer reboxetine study 43	359	2001	Yes <sup>117</sup>	60	No	No	No
Pfizer reboxetine study 32	85	2001		88	No	No	No
Pfizer reboxetine study 96	34	2001		52	No	No	No
Pfizer reboxetine study 71	69	2002		318	No	No	No
Pfizer sertraline study 206	12	1983		721	Yes	Yes	No
Roche oseltamivir studies WV15673 WV15697	1562	1998	Yes <sup>118</sup>	804	Yes	No	No
Roche oseltamivir study WV15670	726	1998	Yes <sup>119</sup>	1032	Yes	No	No
Roche oseltamivir study WV15671	629	1998	Yes <sup>120</sup>	1018	Yes	No	No
Roche oseltamivir study NP15757	59	1998	Yes <sup>121</sup>	445	Yes	No	No
Roche oseltamivir study WV15730	60	1998		525	Yes	No	No
Roche oseltamivir study WV15708	385	1998		661	Yes	No	No
Roche oseltamivir study WV15707	27	1998		458	Yes	No	No
Roche oseltamivir study M76001	1459	1999		1514	Yes	No	No
Roche oseltamivir study WV15799	962	1999	Yes <sup>122</sup>	900	Yes	No	No
Roche oseltamivir study WV15825	572	1999	Yes <sup>123</sup>	875	Yes	No	No
Roche oseltamivir study WV15758	698	1999	Yes <sup>124</sup>	1126	Yes	No	No
Roche oseltamivir studies WV15812 WV15872	404	1999		683	Yes	No	No
Roche oseltamivir studies WV15759 WV15871	335	1999	Yes <sup>125</sup>	1121	Yes	No	No
Roche oseltamivir studies WV15876 WV15819 WV15978	741	2000		973	Yes	No	No
Roche oseltamivir study WP16263	400	2000	Yes <sup>126</sup>	8545	Yes	Yes	No
Roche oseltamivir study WV16193	808	2001	Yes <sup>127</sup>	894	Yes	No	No
Roche oseltamivir study NV16871	329	2004		614	Yes	No	No
Rowtasha arthronat study MA-CT-10-002	80	2010		4924	Yes	Yes	Part
Takeda pioglitazone study PNFP-001	408	1998	Yes <sup>128</sup>	2486	Yes	No	No

CSR=clinical study report; CRFs=case report forms; IPD=individual participant data

\*Date of last participant follow-up (if known).

†No of pages in our possession. Not all reports were complete.

‡Date of CSR (date of last participant follow up is unknown).

§Scheduled end date documented in the CSR (the trial was stopped early).

¶We also have an addendum comprising 101 patients, completed in March 2000

Table 2 | Compression factor ratio of pages in clinical study reports (CSRs) to published study

Published Trial	Length (pages)		Compression factor
	CSR*	Publication	
Oseltamivir study WP16263 <sup>126</sup>	8545	7	1221
Clopidogrel study CAPRIE <sup>68</sup>	96851	11	8805
Paroxetine study 329 <sup>76</sup>	6022	11	547
Paroxetine study 377 <sup>77</sup>	4659	17	274
Paroxetine study 453 <sup>78</sup>	15440	11	1404
Paroxetine study 511 <sup>79</sup>	400	8	50
Paroxetine study 676 <sup>83</sup>	5855	10	586
Paroxetine study 701 <sup>80</sup>	4016	11	365
Paroxetine study 704 <sup>81</sup>	3896	10	390
Paroxetine study 715 <sup>82</sup>	1260	12	105
Paroxetine study 716 <sup>84</sup>	5473	1	5473

\*CSR page totals do not include case report forms, which are unavailable to us.

# Figure

